A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.

American Journal of Respiratory and Critical Care Medicine
Thomas J ScribaHassan Mahomed

Abstract

Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control. To determine the safety and immunogenicity of MVA85A, a novel TB vaccine, among M.tb- and/or HIV-infected persons in a setting where TB and HIV are endemic. An open-label, phase IIa trial was conducted in 48 adults with M.tb and/or HIV infection. Safety and immunogenicity were analyzed up to 52 weeks after intradermal vaccination with 5 × 10(7) plaque-forming units of MVA85A. Specific T-cell responses were characterized by IFN-γ enzyme-linked immunospot and whole blood intracellular cytokine staining assays. MVA85A was well tolerated and no vaccine-related serious adverse events were recorded. MVA85A induced robust and durable response of mostly polyfunctional CD4(+) T cells, coexpressing IFN-γ, tumor necrosis factor-α, and IL-2. Magnitudes of pre- and postvaccination T-cell responses were lower in HIV-infected, compared with HIV-uninfected, vaccinees. No significant effect of antiretroviral therapy on immunogenicity of MVA85A was observed. MVA85A was safe and immunogenic in persons with HIV and/or M.tb infection. These results support further evaluation of safety and ...Continue Reading

References

Dec 1, 1993·International Journal of Epidemiology·L C RodriguesJ G Wheeler
Feb 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W M El-SadrD L Cohn
May 14, 2003·Archives of Internal Medicine·Elizabeth L CorbettChristopher Dye
Dec 17, 2003·The Journal of Experimental Medicine·Souheil-Antoine YounesRafick-Pierre Sekaly
Feb 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brent E PalmerCara C Wilson
Mar 15, 2006·The Journal of Antimicrobial Chemotherapy·Patricia K LeeRichard E Nettles
Jul 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Hans-Willi MittrückerStefan H E Kaufmann
Aug 11, 2007·Journal of the Royal Society, Interface·Christopher Dye, Brian G Williams
Jun 28, 2008·The Journal of Infectious Diseases·Tony HawkridgeHelen McShane
Sep 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Emily K ForbesElma Z Tchilian
Jan 20, 2009·American Journal of Respiratory and Critical Care Medicine·Clare R SanderHelen McShane
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Laith J Abu-RaddadM Elizabeth Halloran
Oct 3, 2009·American Journal of Respiratory and Critical Care Medicine·Barbara KalsdorfRobert J Wilkinson
Jun 19, 2010·American Journal of Respiratory and Critical Care Medicine·Benjamin M N KaginaUNKNOWN other members of the South African Tuberculosis Vaccine Initiative
Jan 17, 1891·British Medical Journal·R Koch
Dec 1, 2010·The Journal of Experimental Medicine·Christof GeldmacherRichard A Koup
Jan 20, 2011·Infection and Immunity·Collin R Diedrich, Joanne L Flynn
Apr 1, 2011·Archives of Disease in Childhood·Mark Hatherill
May 25, 2011·The Journal of Infectious Diseases·Thomas J ScribaHelen McShane
Jul 22, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Cheryl L DayWillem A Hanekom

❮ Previous
Next ❯

Citations

Feb 6, 2014·PloS One·Michele TamerisThomas J Scriba
Oct 17, 2013·American Journal of Respiratory and Critical Care Medicine·Dick Menzies, Payam Nahid
May 9, 2013·Future Virology·Naomi F WalkerRobert J Wilkinson
Jan 1, 2013·Vaccines·Kamalakannan VelmuruganMichael J Brennan
Nov 28, 2012·Expert Review of Vaccines·Neha Dalmia, Alistair J Ramsay
Jan 27, 2016·Human Vaccines & Immunotherapeutics·Matthew K O'Shea, Helen McShane
Nov 3, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Gavish KumarAmla Chopra
Sep 10, 2014·Frontiers in Microbiology·Beatrice O Ondondo
Dec 22, 2012·Microbial Pathogenesis·Jonathan M PittAnne O'Garra
Apr 9, 2013·Expert Review of Vaccines·Joel Meyer, Helen McShane
Apr 28, 2017·Expert Review of Vaccines·Dessislava MarinovaCarlos Martin
Sep 3, 2014·Chest·Zhou XingFiona Smaill
Mar 15, 2014·Current Opinion in Pulmonary Medicine·Stefan H E Kaufmann
Sep 30, 2017·Cells·Josué da Costa Lima-JuniorFátima Conceição-Silva
Aug 7, 2018·Current Opinion in HIV and AIDS·Elisa NemesMark Hatherill
Feb 26, 2014·BMC Infectious Diseases·Carlotta MontagnaniMaurizio de Martino
Nov 8, 2013·Expert Review of Vaccines·Dessislava MarinovaCarlos Martin
Oct 11, 2019·Science Translational Medicine·Melissa-Rose AbrahamsRonald Swanstrom
May 1, 2019·The Cochrane Database of Systematic Reviews·Rufaro KashanguraSamuel Johnson
Feb 16, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Junli LiChuan Qin
Oct 31, 2013·Expert Review of Vaccines·Carmen Elena GómezMariano Esteban
Nov 26, 2015·Journal of Internal Medicine·M Lerm, M G Netea
Nov 18, 2015·World Journal of Gastroenterology : WJG·Faezeh GhasemiZahra Meshkat
Aug 2, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Susan L BaldwinRhea N Coler
Oct 21, 2017·Frontiers in Immunology·Deborah A LewinsohnThomas J Scriba
Jun 6, 2013·European Journal of Immunology·One B DintweThomas J Scriba
Sep 12, 2019·Frontiers in Immunology·Nilu GoonetillekeSarah B Joseph
Nov 2, 2019·Clinical Microbiology Reviews·Suraj B SableThomas J Scriba
Oct 14, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elisa NemesUNKNOWN MVA029 Study Team
Sep 12, 2020·Nature Reviews. Microbiology·Emmanuel MargolinEdward P Rybicki
Oct 22, 2020·NPJ Vaccines·Riti Sharan, Deepak Kaushal
Jan 15, 2017·Microbiology Spectrum·Mark HatherillHelen McShane

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

American Thoracic Association Journals

Discover the latest respiratory research published by the journals from the American Thoracic Society.